首页> 外文期刊>Liver international : >Basal core promoter T1762/A1764 and precore A1896 gene mutations in hepatitis B surface antigen-positive hepatocellular carcinoma: a comparison with chronic carriers.
【24h】

Basal core promoter T1762/A1764 and precore A1896 gene mutations in hepatitis B surface antigen-positive hepatocellular carcinoma: a comparison with chronic carriers.

机译:乙型肝炎表面抗原阳性肝细胞癌的基础核心启动子T1762 / A1764和precore A1896基因突变:与慢性携带者的比较。

获取原文
获取原文并翻译 | 示例

摘要

Background: Chronic hepatitis B virus (HBV) infection is associated with hepatocellular carcinoma (HCC), and specific viral factors have been identified that may increase the risk for HCC development. However, the differences in these viral factors in chronic carriers who seldom develop HCC compared with HCC patients have not been adequately evaluated. Methods: From 1989 to 2005, 101 hepatitis B surface antigen-positive patients presented to our clinic with HCC. Baseline basal core promoter (BCP) T1762/A1764 mutants, precore (PC) A1896 mutants, HBV genotypes and HBV DNA in HCC patients were compared with 67 chronic carriers who had been followed for a mean of 112.1+/-77.7 standard deviation months. Results: At baseline, HCC patients had lower levels of serum albumin, but higher values of alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, bilirubin and alpha-foetoprotein than those of chronic carriers (P<0.001 for all comparisons). The presence of genotype C, higher frequencies of PC A1896 mutants, BCP T1762/A1764 mutants and higher circulating levels of HBV DNA were more frequently detected in HCC patients than that in chronic carriers (P<0.001 for all observations). Logistic regression analysis revealed that BCP T1762/A1764 mutants [odds ratio (OR) 11.14, 95% confidence interval (CI) 3.05-40.72; P<0.001] and PC A1896 mutants (OR 3.75, 95% CI 1.14-12.34; P<0.05) were significantly associated with HCC development. Conclusion: Our results indicate that the presence of BCP and PC mutations significantly increases the risk for HCC in chronic hepatitis B patients. These mutations were less often detected in chronic carriers who seldom develop HCC.
机译:背景:慢性乙型肝炎病毒(HBV)感染与肝细胞癌(HCC)相关,并且已鉴定出可能增加HCC发生风险的特定病毒因素。但是,与HCC患者相比,在很少发生HCC的慢性携带者中这些病毒因子的差异尚未得到充分评估。方法:从1989年至2005年,共有101例乙型肝炎表面抗原阳性患者被带入我们的HCC门诊。将HCC患者的基线基础核心启动子(BCP)T1762 / A1764突变体,precore(PC)A1896突变体,HBV基因型和HBV DNA与67例慢性携带者进行了比较,平均随访时间为112.1 +/- 77.7个标准差月。结果:基线时,HCC患者的血清白蛋白水平较低,但碱性磷酸酶,天冬氨酸转氨酶,丙氨酸转氨酶,胆红素和甲胎蛋白的水平高于慢性携带者(所有比较均P <0.001)。与慢性携带者相比,在HCC患者中更频繁地检测到基因型C,PC A1896突变体,BCP T1762 / A1764突变体的频率较高以及HBV DNA的循环水平较高(所有观察结果均P <0.001)。 Logistic回归分析表明,BCP T1762 / A1764突变体[比值比(OR)为11.14,95%置信区间(CI)为3.05-40.72; P <0.001]和PC A1896突变体(OR 3.75,95%CI 1.14-12.34; P <0.05)与HCC发生显着相关。结论:我们的结果表明,慢性乙型肝炎患者中BCP和PC突变的存在显着增加了HCC的风险。这些突变在很少发展为HCC的慢性携带者中很少发现。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号